Trial Search Results

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

Stanford is currently accepting patients for this trial.

Lead Sponsor:


Stanford Investigator(s):


  • Drug: Abicipar Pegol
  • Drug: Ranibizumab
  • Other: Sham Procedure


Phase 3


Inclusion Criteria:

   - Diagnosis of age-related macular degeneration in at least 1 eye

   - Best corrected visual acuity of 20/40 to 20/320 in the study eye

   - Best corrected visual acuity of 20/200 or better in the non-study eye

Exclusion Criteria:

   - History of vitrectomy, macular surgery, or glaucoma surgery in the study eye

   - Cataract or refractive surgery in the study eye within the last 3 months

Ages Eligible for Study

50 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305